| Literature DB >> 33910911 |
Shihan Zhen1, Yanan Ma2, Yanshuo Han2, Zhongyi Zhao2, Xuelian Yang1, Deliang Wen3.
Abstract
INTRODUCTION: Childhood obesity (OB) and metabolic syndrome (MetS) have become a worldwide health problem. Comparative proteomic approaches are widely used in human OB to analyze protein changes in blood plasma. The present study determined the galectin-3 binding protein (galectin-3BP) expression level in different weight categories and assessed the associations between galectin-3BP and OB and MetS. RESEARCH DESIGN AND METHODS: The current study included 932 Chinese adolescents 13-18 years of age. The biochemical and anthropometric variables of all the subjects were evaluated using standardized procedures. The differentially expressed proteins (DEPs) were investigated among 60 adolescents (20 normal weight, 20 overweight and 20 obese) using tandem mass tag (TMT) quantitative proteomics. The serum galectin-3BP level was measured using ELISA. The associations between galectin-3BP and OB and MetS were analyzed in 932 adolescents using multiple logistic regression analyses.Entities:
Keywords: adolescent health; metabolic syndrome; obesity; proteomics
Mesh:
Substances:
Year: 2021 PMID: 33910911 PMCID: PMC8094345 DOI: 10.1136/bmjdrc-2020-001894
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Figure 1Detailed functional classifications of the identified proteins. (A–C) GO analysis was performed to identify the functional significance for each screened protein. (D–F) KEGG pathway analysis was used to elucidate the enrichment pathway. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 2Flowcharts to obtain intersection in the trial: the 26 protein expressions in 60 adolescents’ plasma and the screening details of protein based on intersection analysis.
Characteristics of the study population according to tertiles of galectin-3BP level
| Characteristic | Tertile 1 (n=310) | Tertile 2 (n=311) | Tertile 3 (n=311) |
| Age (years), mean (SD) | 16.27 (1.04) | 16.27 (1.02) | 16.05 (0.91) |
| Girls, n (%) | 144 (46.45) | 148 (47.59) | 190 (61.09) |
| Anthropometry | |||
| BMI z-score, mean (SD) | 0.06 (1.17) | 0.43 (1.36) | 0.65 (1.36) |
| Waist circumference, mean (SD) | 71.95 (8.60) | 75.00 (11.54) | 75.97 (12.01) |
| Weight status, n (%) | |||
| NW | 250 (80.65) | 204 (65.59) | 181 (58.20) |
| OW | 40 (12.90) | 61 (19.61) | 73 (23.47) |
| OB | 20 (6.45) | 46 (14.79) | 57 (18.33) |
| MetS outcomes | |||
| MetS, n (%) | 8 (2.58) | 15 (4.82) | 23 (7.40) |
| Center obesity, n (%) | 48 (15.48) | 92 (29.58) | 106 (34.08) |
| Hypertension, n (%) | 69 (22.26) | 66 (21.22) | 82 (26.37) |
| Hyperglycemia, n (%) | 3 (0.97) | 5 (1.61) | 5 (1.61) |
| High_TG, n (%) | 26 (8.39) | 30 (9.65) | 26 (8.36) |
| Low_HDL-C, n (%) | 35 (11.29) | 43 (13.83) | 48 (15.43) |
| Laboratory examinations | |||
| FPG (mmol/L), median (Q1–Q3) | 4.28 (4.0–4.56) | 4.25 (3.96–4.53) | 4.31 (4.05–4.6) |
| TG (mmol/L), median (Q1–Q3) | 0.71 (0.53–0.98) | 0.76 (0.55–1.04) | 0.80 (0.59–1.07) |
| ALT (U/L), median (Q1–Q3) | 10 (8–16) | 10 (8–17) | 10 (8–17) |
| AST (U/L), median (Q1–Q3) | 15 (13–18) | 16 (13–19) | 15 (13–18) |
| ALP (U/L), median (Q1–Q3) | 96 (76–126) | 93 (77–117) | 93 (74–126) |
| GGT (U/L), median (Q1–Q3) | 16 (13–20) | 16 (13–22) | 16 (13–22) |
| C1q (mg/L), median (Q1–Q3) | 176.0 (156.6–201.4) | 177.6 (154.6–200.2) | 184.5 (167.5–209.5) |
| HDL-C (mmol/L), median (Q1–Q3) | 1.31 (1.14–1.50) | 1.30 (1.11–1.51) | 1.28 (1.13–1.51) |
| LDL-C (mmol/L), median (Q1–Q3) | 2.08 (1.70–2.50) | 2.12 (1.79–2.52) | 2.19 (1.80–2.58) |
| Apolipoprotein A1 (g/L), median (Q1–Q3) | 1.30 (1.21–1.42) | 1.31 (1.20–1.41) | 1.32 (1.19–1.45) |
| Apolipoprotein B (g/L), median (Q1–Q3) | 0.61 (0.52–0.72) | 0.63 (0.54–0.73) | 0.66 (0.56–0.76) |
| Small dense low-density lipoprotein cholesterol (mmol/L), median (Q1–Q3) | 0.42 (0.33–0.52) | 0.42 (0.33–0.51) | 0.43 (0.34–0.53) |
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, Body Mass Index; FPG, fasting plasma glucose; galectin-3BP, galectin-3 binding protein; GGT, gamma-glutamyl transferase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; NW, normal weight; OB, obesity; OW, overweight; TG, triglyceride.
Multivariable adjusted ORs and 95% CI for OW, OB and MetS across tertiles of galectin-3BP level
| Tertiles, OR (95% CI) | P value for trend | |||
| Tertile 1 (n=310) | Tertile 2 (n=311) | Tertile 3 (n=311) | ||
| OW+OB | ||||
| Age-adjusted model | 1 (reference) | |||
| Multiple-adjusted model | 1 (reference) | |||
| OB | ||||
| Age-adjusted model | 1 (reference) | |||
| Multiple-adjusted model | 1 (reference) | |||
| MetS | ||||
| Age-adjusted model | 1 (reference) | 1.92 (0.80 to 4.61) | ||
| Multiple-adjusted model | 1 (reference) | 1.58 (0.59 to 4.24) | ||
Multiple-adjusted model: adjusted for age (in years), sex (boys vs girls), ALT (U/L), AST (U/L), ALP (U/L), and GGT (U/L). P value for trend was obtained by adjusting tertiles of galectin-3BP level as a continuous variable. P values of <0.05 are in bold.
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; galectin-3BP, galectin-3 binding protein; GGT, gamma-glutamyl transferase; MetS, metabolic syndrome; OB, obesity; OW, overweight.
Figure 3ROC curves of tertiles of galectin-3BP level for MetS. The area under the ROC curve was 0.85 (95% CI 0.79 to 0.91). Galectin-3BP, galectin-3 binding protein; MetS, metabolic syndrome; ROC, receiver operating characteristic.